


# NDec\* clinical development program

Sickle Cell Disease



\*NDec is an investigational, oral formulation of a combination of decitabine and tetrahydrouridine in development for the treatment of sickle cell disease

SCD, Sickle Cell Disease


<sup>1</sup>NCT01685515, FHD: First Human Dose, Molokie R et al. PLoS Med 2017 Sep 7;14(9):e1002382. doi: 10.1371/journal.pmed.1002382.

<sup>2</sup>NCT05405114 <sup>3</sup>NCT03828084, Sauntharajah Y. et al: Poster #29; presented at ASCAT (Annual SC and Thalassemia meeting), London Oct 20-22, 2022. <sup>4</sup>NCT04086238, Andemariam B. et al: Poster # 2379; accepted/to be presented at ASH, New Orleans, LA Dec 10-13, 2022.



# Etavopivat\* clinical development program

Sickle Cell Disease & Thalassemia



\*Etavopivat (FT-4202) is an investigational, oral, small molecule activator of erythrocyte pyruvate kinase (PKR) in development for the treatment of sickle cell disease (SCD) and other hemoglobinopathies

SCD, Sickle Cell Disease; TD SCD, transfusion dependent sickle cell disease; TD Thal, transfusion dependent thalassemia; non-TD Thal, non-transfusion dependent thalassemia; TD, transfusion dependent

<sup>1</sup>NCT03815695, Forsyth S, et al. Clin Pharmacol Drug Dev. 2022 May;11(5):654-665. doi: 10.1002/cpdd.1058. Epub 2022 Jan 12.. <sup>2</sup>NCT04624659

<sup>3</sup>NCT04987489



novo nordisk®